INNOVATIVE SOLUTIONS & SUPPORT INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INNOVATIVE SOLUTIONS & SUPPORT INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $3.65M | Dec 21, 2018 |
| FY2018 | Jun 30, 2018 | $3.39M | Dec 21, 2018 |
| FY2018 | Mar 31, 2018 | $3.73M | Dec 21, 2018 |
| FY2018 | Dec 31, 2017 | $3.09M | Dec 21, 2018 |
| FY2018 | Sep 30, 2017 | $4.23M | Dec 21, 2018 |
| FY2018 | Jun 30, 2017 | $4.54M | Dec 21, 2018 |
| FY2018 | Mar 31, 2017 | $4.65M | Dec 21, 2018 |
| FY2018 | Dec 31, 2016 | $3.37M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $6.22M | Dec 15, 2017 |
| FY2017 | Jun 30, 2016 | $6.50M | Dec 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $40.51M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $25.91M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $21.31M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $16.67M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $12.78M | Jan 12, 2024 |
| FY2020 | Sep 30, 2020 | $3.51M | Dec 22, 2020 |
| FY2020 | Jun 30, 2020 | $3.39M | Dec 22, 2020 |
| FY2020 | Mar 31, 2020 | $2.30M | Dec 22, 2020 |
| FY2020 | Dec 31, 2019 | $2.60M | Dec 22, 2020 |
| FY2020 | Sep 30, 2019 | $2.86M | Dec 22, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.63M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $7.00M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $6.03M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $5.52M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $5.06M | Jan 12, 2024 |
| FY2022 | Sep 30, 2020 | $3.27M | Dec 16, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $20.07M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $9.66M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $7.36M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $7.22M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $3.90M | Jan 12, 2024 |
| FY2020 | Sep 30, 2020 | $1.22M | Dec 22, 2020 |
| FY2020 | Jun 30, 2020 | $1.24M | Dec 22, 2020 |
| FY2020 | Mar 31, 2020 | $51.8K | Dec 22, 2020 |
| FY2020 | Dec 31, 2019 | $231.8K | Dec 22, 2020 |
| FY2020 | Sep 30, 2019 | $873.0K | Dec 22, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.99M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $4.14M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $3.13M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $2.71M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $2.62M | Jan 12, 2024 |
| FY2022 | Sep 30, 2020 | $2.96M | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | $2.49M | Dec 22, 2021 |
| FY2020 | Sep 30, 2018 | $3.58M | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $4.46M | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | $4.87M | Dec 21, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $16.45M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $12.11M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $10.82M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $6.75M | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | $6.26M | Jan 12, 2024 |
| FY2022 | Sep 30, 2020 | $6.10M | Dec 16, 2022 |
| FY2021 | Sep 30, 2019 | $5.88M | Dec 22, 2021 |
| FY2020 | Sep 30, 2018 | $6.67M | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $3.74M | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | $9.17M | Dec 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $13.30M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $5.80M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $2.10M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $6.09M | Dec 30, 2024 |
| FY2022 | Sep 30, 2021 | $4.59M | Dec 16, 2022 |
| FY2023 | Sep 30, 2020 | $4.59M | Jan 12, 2024 |
| FY2021 | Sep 30, 2019 | $2.11M | Dec 22, 2021 |
| FY2020 | Sep 30, 2018 | ($1.74M) | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $6.07M | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | $3.56M | Dec 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.51M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $657.8K | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $298.4K | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $161.2K | Dec 30, 2024 |
| FY2022 | Sep 30, 2021 | $340.7K | Dec 16, 2022 |
| FY2023 | Sep 30, 2020 | $340.7K | Jan 12, 2024 |
| FY2021 | Sep 30, 2019 | $81.3K | Dec 22, 2021 |
| FY2020 | Sep 30, 2018 | $2.55M | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $153.0K | Dec 23, 2019 |
| FY2018 | Sep 30, 2016 | $352.8K | Dec 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $103.36M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $82.38M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $62.96M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $34.71M | Jan 12, 2024 |
| FY2022 | Sep 30, 2021 | $27.09M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $41.55M | Dec 22, 2021 |
| FY2021 | Oct 1, 2019 | $38.69M | Dec 22, 2021 |
| FY2021 | Sep 30, 2019 | $38.56M | Dec 22, 2021 |
| FY2019 | Sep 30, 2018 | $37.63M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $41.04M | Dec 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $38.76M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $35.74M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $24.32M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $3.96M | Jan 12, 2024 |
| FY2022 | Sep 30, 2021 | $2.50M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $13.78M | Dec 22, 2021 |
| FY2021 | Oct 1, 2019 | $2.39M | Dec 22, 2021 |
| FY2021 | Sep 30, 2019 | $2.35M | Dec 22, 2021 |
| FY2019 | Sep 30, 2018 | $3.48M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $3.43M | Dec 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $64.60M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $46.64M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $38.64M | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | $30.75M | Dec 30, 2024 |
| FY2024 | Sep 30, 2021 | $24.59M | Dec 30, 2024 |
| FY2023 | Sep 30, 2020 | $27.77M | Jan 12, 2024 |
| FY2022 | Sep 30, 2019 | $36.21M | Dec 16, 2022 |
| FY2021 | Sep 30, 2018 | $34.15M | Dec 22, 2021 |
| FY2020 | Sep 30, 2017 | $37.61M | Dec 22, 2020 |
| FY2019 | Sep 30, 2016 | $32.85M | Dec 23, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.70M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $5.21M | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | $3.56M | Dec 23, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $28.29M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $12.67M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $5.67M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | ($359.0K) | Jan 12, 2024 |
| FY2022 | Sep 30, 2021 | ($5.88M) | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | ($2.34M) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $5.57M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $3.72M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $7.37M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $2.81M | Dec 15, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.69M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $539.0K | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $3.10M | Dec 30, 2024 |
| FY2023 | Sep 30, 2022 | $17.25M | Jan 12, 2024 |
| FY2022 | Sep 30, 2021 | $8.27M | Dec 16, 2022 |
| FY2021 | Sep 30, 2020 | $12.60M | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $22.42M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $20.39M | Dec 23, 2019 |
| FY2018 | Sep 30, 2017 | $24.68M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $18.77M | Dec 15, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $24.38M | Dec 23, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | 0 | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | 0 | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | 0 | Jan 12, 2024 |
| FY2020 | Sep 30, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Dec 22, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Dec 22, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2023 | 0 | Dec 23, 2025 |
| FY2024 | Sep 30, 2022 | 0 | Dec 30, 2024 |
| FY2023 | Sep 30, 2021 | 0 | Jan 12, 2024 |
| FY2020 | Sep 30, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Dec 22, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Dec 22, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Dec 22, 2020 |